Edition:
United States

Sanofi SA (SNY)

SNY on New York Consolidated

49.08USD
20 Sep 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$49.08
Open
--
Day's High
--
Day's Low
--
Volume
1,287
Avg. Vol
1,466,309
52-wk High
$50.24
52-wk Low
$36.81

Select another date:

Wed, Sep 20 2017

BRIEF-Alnylam's genetic disease drug meets main goal in phase 3 study

* Sanofi and Alnylam report positive topline results from APOLLO phase 3 study of patisiran in Hereditary ATTR (HATTR) amyloidosis patients with polyneuropathy

BRIEF-Kuehne und Nagel awarded logistics contract by Sanofi

* SANOFI AWARDS LOGISTICS CONTRACT TO KUEHNE + NAGEL‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Daily blood glucose measures in phase 3 clinical trials showed better stability with Sanofi's toujeo vs insulin glargine 100 units/ml

* Daily blood glucose measures in phase 3 clinical trials demonstrated better stability with Sanofi's toujeo versus insulin glargine 100 units/ml

Sanofi indicates dupilumab could be used to treat nasal polyps

PARIS Sanofi's chief executive said that its key drug dupilumab could possibly be used to treat nasal polyps as well as eczema and asthma.

Sanofi indicates dupilumab could be used to treat nasal polyps

PARIS, Sept 12 Sanofi's chief executive said that its key drug dupilumab could possibly be used to treat nasal polyps as well as eczema and asthma.

BRIEF-Sanofi's Soliqua 100/33 provided earlier blood sugar control than insulin glargine 100 units/ml

* Sanofi's soliqua 100/33 provided earlier blood sugar control than insulin glargine 100 units/ml

Regeneron, Sanofi asthma drug data fails to excite investors

PARIS Shares of Regeneron Inc and Sanofi SA slid on Monday after late-stage trial data for their asthma drug, dupilumab, fell short of investor expectations.

UPDATE 2-Regeneron, Sanofi asthma drug data fails to excite investors

PARIS, Sept 11 Shares of Regeneron Inc and Sanofi SA slid on Monday after late-stage trial data for their asthma drug, dupilumab, fell short of investor expectations.

BRIEF-Regeneron, Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma

* Regeneron and Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma

Sanofi and Regeneron announce positive dupilumab topline results

PARIS, Sept 11 Drugmakers Sanofi and Regeneron announced on Monday positive results for their dupilumab product, which helps treat allergic inflammation.

Select another date: